Display options
Cite
Zhu Y, Cui PJ, Yao J, et al. Efficacy of Transarterial Chemoembolisation with or without Antiviral Therapy for Patients with Hepatocellular Carcinoma after Radical Hepatectomy. Gastroenterol Res Pract. 2018;2018:6414759doi: 10.1155/2018/6414759.
Zhu, Y., Cui, P. J., Yao, J., Zhang, Z. Y., & Yang, J. (2018). Efficacy of Transarterial Chemoembolisation with or without Antiviral Therapy for Patients with Hepatocellular Carcinoma after Radical Hepatectomy. Gastroenterology research and practice, 20186414759. https://doi.org/10.1155/2018/6414759
Zhu, Yin, et al. "Efficacy of Transarterial Chemoembolisation with or without Antiviral Therapy for Patients with Hepatocellular Carcinoma after Radical Hepatectomy." Gastroenterology research and practice vol. 2018 (2018): 6414759. doi: https://doi.org/10.1155/2018/6414759
Zhu Y, Cui PJ, Yao J, Zhang ZY, Yang J. Efficacy of Transarterial Chemoembolisation with or without Antiviral Therapy for Patients with Hepatocellular Carcinoma after Radical Hepatectomy. Gastroenterol Res Pract. 2018 Apr 01;2018:6414759. doi: 10.1155/2018/6414759. eCollection 2018. PMID: 29805444; PMCID: PMC5902052.
Copy Download .nbib Format: NLM
Share it on

Gastroenterol Res Pract. 2018 Apr 01;2018:6414759. doi: 10.1155/2018/6414759. eCollection 2018.

Efficacy of Transarterial Chemoembolisation with or without Antiviral Therapy for Patients with Hepatocellular Carcinoma after Radical Hepatectomy.

Gastroenterology research and practice

Yin Zhu, Pei-Jing Cui, Jing Yao, Zheng-Yun Zhang, Jun Yang

Affiliations

  1. Department of Surgery, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 200233, China.
  2. Department of Geriatrics, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China.

PMID: 29805444 PMCID: PMC5902052 DOI: 10.1155/2018/6414759

Abstract

OBJECTIVE: This study aimed at assessing the effects of transcatheter arterial chemoembolisation (TACE) and antiviral therapy on improving the prognosis of patients with hepatocellular carcinoma (HCC) after radical hepatectomy.

METHODS: This study reviewed the data of 120 patients with HCC who received either radical hepatectomy alone (control group), radical hepatectomy with postoperative TACE (TACE group) or radical hepatectomy with combined postoperative TACE, and antiviral therapy (combined group) from January 2000 to May 2015. To reduce the impact of the possible biases on the conclusion of this study to the minimum, the cases with similar demographic and clinicopathological characteristics were collected and 40 cases were assigned into each group. Recurrence, disease-free survival (DFS), and overall survival (OS) rates were compared.

RESULTS: Median follow-up period was 54.26 ± 22.65 months with a range of 17-110 months. Recurrence after radical surgery was observed for 39 (97.5%) patients in the TACE group, 32 (80%) in the combined group, and 40 (100%) in the control group with median recurrence duration of 33, 43, and 16.5 months, respectively. Postoperative TACE with or without antiviral therapy significantly prolonged the DFS rate compared with radical hepatectomy alone (

CONCLUSION: TACE is an appropriate therapy for HCC patients after radical hepatectomy. When combined with antiviral therapy, this treatment may further prolong the recurrence time and thus lead to high DFS and OS rates.

References

  1. World J Gastroenterol. 2005 Dec 21;11(47):7391-400 - PubMed
  2. Gastroenterology. 1991 Jan;100(1):182-8 - PubMed
  3. Hepatogastroenterology. 2006 Mar-Apr;53(68):249-52 - PubMed
  4. Tumour Biol. 2015 Aug;36(8):6277-84 - PubMed
  5. Hepatogastroenterology. 2013 Mar-Apr;60(122):248-51 - PubMed
  6. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:138-43 - PubMed
  7. Asia Pac J Clin Oncol. 2012 Dec;8(4):356-61 - PubMed
  8. Chin Med J (Engl). 2013 Mar;126(5):855-9 - PubMed
  9. Hepatobiliary Pancreat Dis Int. 2010 Feb;9(1):33-7 - PubMed
  10. Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50 - PubMed
  11. World J Gastroenterol. 2004 Oct 1;10(19):2791-4 - PubMed
  12. J Med Virol. 2008 Apr;80(4):591-7 - PubMed
  13. World J Gastroenterol. 2010 Dec 21;16(47):5993-6000 - PubMed
  14. J Hepatol. 2003 Feb;38(2):200-7 - PubMed
  15. Ann Surg Oncol. 2010 Jan;17(1):179-85 - PubMed
  16. Radiology. 1976 Sep;120(3):539-45 - PubMed
  17. Kaohsiung J Med Sci. 2011 Dec;27(12):554-9 - PubMed
  18. J Gastroenterol Hepatol. 2007 Nov;22(11):1929-35 - PubMed
  19. Hepatobiliary Pancreat Dis Int. 2009 Apr;8(2):124-33 - PubMed
  20. Tumour Biol. 2014 Oct;35(10):9459-68 - PubMed
  21. Acta Med Okayama. 2005 Oct;59(5):217-24 - PubMed
  22. Scand J Gastroenterol. 2014 Jun;49(6):649-61 - PubMed
  23. Hepatol Res. 2010 Oct;40(10):943-53 - PubMed
  24. J Hepatol. 2004 Sep;41(3):427-35 - PubMed
  25. Am J Gastroenterol. 2008 Jul;103(7):1663-73 - PubMed
  26. Liver Int. 2013 Apr;33(4):595-604 - PubMed
  27. Biomed Pharmacother. 2016 Dec;84:1679-1688 - PubMed
  28. Hepatogastroenterology. 1999 Mar-Apr;46(26):1083-8 - PubMed
  29. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD001199 - PubMed
  30. J Cancer Res Clin Oncol. 1995;121(6):364-6 - PubMed
  31. Zhonghua Wai Ke Za Zhi. 2007 May 1;45(9):587-90 - PubMed

Publication Types